Clinical relevance of molecular markers in lung cancer

Surgical Oncology

Volumn 11, Issue 4, 2002, Pages 167-179

  Iyengar, P ^a,b   Tsao, M S ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomarkers; Diagnosis; Early detection; Molecular pathology; Prognostic Markers

Indexed keywords

BETA TUBULIN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; RAS PROTEIN; RETINOIC ACID RECEPTOR; THYROID TRANSCRIPTION FACTOR 1;

BIOTRANSFORMATION; CANCER DIAGNOSIS; CANCER GROWTH; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LIVER CELL; LUNG CARCINOMA; METHYLATION; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEUROENDOCRINOLOGY; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; PUBLICATION; RETINOBLASTOMA; REVIEW;

GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036889905     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(02)00047-6     Document Type: Review

References (131)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics 2001. CA Cancer Journal Clinical. 51:2001;15-36.
2. Travis WD, Colby RV, Corrin B, Shimosato Y, Brambilla E, in Collaboration with Sobin LH and Pathologists from 14 Countries. WHO international classification of tumours. Histological typing of lung and pleural tumours. Berlin: Springer, 1999.
3. Fong K.M., Sekido Y., Minna J.D. Molecular pathogenesis of lung cancer. Journal of Thoracic and Cardiovascular Surgery. 118:1999;1136-1152.
4. Rom W.N., Hay J.G., Lee T.C., Jiang Y., Tchou-Wong K.-.M. Molecular and genetic aspects of lung cancer. American Journal of Respiratory and Critical Care Medicine. 161:2000;1355-1367.
5. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.-.P. Alterations in DNA methylation - A fundamental aspect of neoplasia. Advances in Cancer Research. 72:1998;141-196.
6. Shimosato Y. Pulmonary neoplasms. Sternburg S. Diagnostic surgical pathology. 1999;1069-1116 Lippincott-Williams & Wilkins, Philadelphia.
7. Wang N.P., Zee S., Zarbo R.J., Bacchi C.E., Gown A.M. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Applied Immunohistochemistry. 3:1995;99-107.
8. Chu P., Wu E., Weiss L.M. Cytokeratin 7 and Cytokerain 20 expression in epithelial neoplasms. a survey of 435 cases Modern Pathology. 13:2000;962-972.
9. Pelosi G., Fraggetta F., Pasini F., Maisonneuve P., Sonzogni A., Iannucci A., Terzi A., Bresaola E., Valduga F., Lupo C., Viale G. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. American Journal of Surgical Pathology. 25:2001;363-372.
10. Ordonez N.G. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Advances in Anatomy and Pathology. 7:2000;123-127.
11. Folpe A.L., Gown A.M., Lamps L.W., Garcia R., Dail D.H., Zarbo R.J., Schmidt R.A. Thyroid transcription factor-1. immunohistochemical evaluation in pulmonary neuroendocrine tumors Modern Pathology. 12:1999;5-8.
12. Cury P.M., Butcher C., Fisher C., Corrin B., Nicholson A.G. Value of mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Modern Pathology. 13:2000;107-112.
13. Ordonez N.G. Value of thyroid transcription factor-1, E-cadherin, BG8, WT-1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and non-pulmonary adenocarcinoma. American Journal of Surgical Pathology. 24:2000;598-606.
14. Mountain C.F. Revisions in the international system of staging for lung cancer. Chest. 111:1997;1710-1717.
15. Maki E., Feld R. Prognostic factors in patients with non-small cell lung cancer. A critique of the world literature. Lung Cancer. 7:1991;27-35.
16. Mountain C.F. New prognostic factors in lung cancer. Chest. 108:1995;246-254.
17. Graziano S.L. Non-small cell lung cancer. clinical value of new biologic predictors Lung Cancer. 17(Suppl.1):1997;S37-S58.
18. Bos J.L. Ras oncogenes in human cancer. a review Cancer Research. 49:1989;4682-4689.
19. Burgering B.M.T., Bos J.L. Regulation of ras-mediated signaling. more than one way to skin a cat Trends in Biochemical Science. 20:1995;18-22.
20. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Letters. 171:2001;1-10.
21. Klemke R.L., Cai S., Giannini A.L., Gallagher P.J., de Lanerolle P., Cheresh D.A. Regulation of cell motility by mitogen-activated protein kinase. Journal of Cell Biology. 137:1997;481-492.
22. Rodenhuis S., Slebos R.J.C. Clinical significance of ras oncogene activation in human lung cancer. Cancer Research. 52(Suppl.):1992;2665-2955.
23. Tsao M.-.S., Liu N., Nicklee T., Shepherd F., Viallet J. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clinical Cancer Research. 3:1997;1807-1814.
24. Graziano S.L., Gamble G.P., Newman N.B., Abbott L.Z., Rooney A., Mookherjee S., Lamb M.L., Kohman L.J., Poiesz B.J. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small cell lung cancer. Journal of Clinical Oncology. 17:1999;668-675.
25. Slebos R.J.C., Kibbaelaar R.E., Dalesio O., Kooistra A., Stam J., Meijer C.J., Wagennar S.S., Vanderschueren R.G., van Zandwijk N., Mooi W.J., Bos J.L., Rodenhuis S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. New England Journal of Medicine. 32:1990;561-565.
26. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell. 103:2000;211-225.
27. Prenzel N., Fischer O.M., Streit S., Hart S., Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocrine-related Cancer. 8:2001;11-31.
28. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The erbB signalling network. receptor heterodimerization in development and cancer EMBO Journal. 19:2000;3159-3167.
29. Rusch V., Klimstra D., Venkatraman E., Pisters P.W.T., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor a is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clinical Cancer Research. 3:1997;515-522.
30. Hsieh E.T.K., Shepherd F.A., Tsao M.-.S. Co-expression of epidermal growth factor receptor and transforming growth factor-. α is independent of ras mutations in lung adenocarcinoma Lung Cancer. 29:2000;151-157.
31. Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. European Journal of Cancer. 37:2001;S9-S15.
32. Pastorino U., Andreola S., Tagliabue E., Pezella F., Incarbone M., Sozzi G., Buyse M., Menard S., Pierotti M., Rilke F. Immunohistochemical markers in stage I lung cancer. relevance to prognosis Journal of Clinical Oncology. 15:1997;2858-2865.
33. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Research. 50:1990;7077-7080.
34. Cox G., Jones L., O'Byrne K.J.O. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clinical Cancer Research. 6:2000;2349-2355.
35. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J., Salonga D., Holscher A.H., Danenberg P.V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clinical Cancer Research. 7:2001;1850-1855.
36. Ohsaki Y., Tanno S., Fujita Y., Toyoshima E., Fujiuchi S., Nishigaki Y., Ishida S., Nagase A., Miyokawa N., Hirata S., Kikuchi K. Epidermal growth factor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncology Report. 7:2000;603-607.
37. Cox G., Vyberg M., Melgaard B., Askaa J., Oster A., O'Byrne K.J.O. Herceptest. HER2 expression and gene amplification in non-small cell lung cancer International Journal of Cancer. 92:2001;480-483.
38. neu expression in human lung adenocarcinomas predicts shortened survival Cancer Research. 50:1990;5184-5191.
39. Kim Y.-.C., Park K.-.O., Kern J Park C.-.S., Lim S.-.C., Jang A.-.S., Yang J.-.B. The interactive effect of Ras, HER2, p53, and Bcl2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer. 22:1998;181-190.
40. Cox G., Jones J.L., Andi A., Waller D.A., O'Byrne K.J. A biological staging model for operable non-small cell lung cancer. Thorax. 56:2001;561-566.
41. Park M., Dean M., Kaul K., Braun M.J., Gonda M.A., Vande Woude G.F. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proceedings of the National Academy of Sciences, USA. 84:1987;6379-6383.
42. Jeffers M., Rong S., Vande Woude G.F. Hepatocyte growth factor/scatter factor-Met signalling in tumorigenicity and invasion/metastasis. Journal of Molecular Medicine. 74:1996;505-513.
43. To C.T.T., Tsao M.S. The roles of hepatocyte growth factor/scatter factor and Met receptor in human cancer (review). Oncology Report. 5:1998;1013-1024.
44. Weidner K.M., Behrens J., Vandekerckhove J., Birchmeier W. Scatter factor. molecular characteristics and effect on the invasiveness of epithelial cells Journal of Cell Biology. 111:1990;2097-2121.
45. Rosen E.M., Nigam S.K., Goldberg I.D. Scatter factor and the c-met receptor: A paradigm for mesenchymal/epithelial interaction. Journal of Cell Biology. 127:1994;1783-1787.
46. Tsao M.S., Yang Y., Marcus A., Liu N., Mou L. Hepatocyte growth factor (HGF) and its isoforms are predominantly expressed by epithelial cells in normal lung and primary non-small cell lung cancer. Human Pathology. 32:2001;57-65.
47. Siegfried J.M., Weissfeld L.A., Singh-Kaw P., Weyant R.J., Testa J.R., Landreneau R.J. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Research. 57:1997;433-439.
48. Takanami I., Tanana F., Hashizume T., Kikuchi K., Yamamoto Y., Yamamoto T., Kodaira S. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas. an evaluation of their expression as prognostic markers Oncology. 53:1996;392-397.
49. Hunter T., Pines J. Cyclins and cancer II. cyclin D and CDK inhibitors come of age Cell. 79:1994;573-582.
50. Harper J.W., Elledge S.J. Cdk inhibitors in development and cancer. Current Opinion in Genetic Development. 6:1996;56-64.
51. Liggett W.H. Jr., Sidransky D. Role of the p16 tumor suppressor gene in cancer. Journal of Clinical Oncology. 16:1998;1197-1206.
52. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C, Slamon DJ and the Lung Cancer Study Group. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. Oncogene 1993;8:1913-9.
53. Kratzke R.A., Greatens T.M., Rubins J.B., Maddaus M.A., Niewoehner D.E., Niehans G.A., Geradts J. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Research. 56:1996;3415-3420.
54. Baldi A., Esposito V., De Luca A., Howard C.M., Mazzarella G., Baldi F., Caputi M., Giordano A. Differential expression of the retinoblastoma gene family member pRb/p105, p107 and pRb2/p130 in lung cancer. Clinical Cancer Research. 2:1996;1239-1245.
55. Mishina T., Dosaka-Akita H., Hommura F., Nishi M., Kojima T., Ogura S., Shimizu M., Katoh H., Kawakami Y. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clinical Cancer Research. 6:2000;11-16.
56. Fukuse T., Hirata T., Naiki H., Hitomi S., Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Research. 60:2000;242-244.
57. Müller-Tidow C., Metzger R., Kügler K., Diederichs S., Idos G., Thomas M., Dockhorn-Dworniczak B., Schneider P.M., Koeffler P., Berdel W.E., Serve H. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Research. 61:2001;647-653.
58. Dosaka-Akita H., Hommura F., Mishina T., Ogura S., Shimizu M., Katoh H., Kawakami Y. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21. different roles of G1 cyclins in cell proliferation and prognosis Cancer Research. 61:2001;2500-2504.
59. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., Yu R., Draetta G.F., Rolfe M. Role of the ubiquitin-proteosome pathway in regulating the abundance of the cyclin dependent kinase inhibitor p27. Science. 269:1995;682-685.
60. kip1, a cyclin-dependent kinase inhibitor and potential mediator of extracellular antimitogenic signals Cell. 78:1994;59-66.
61. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M., Giordano G.G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27Kip1 in non-small cell lung cancer. Cancer Research. 57:1997;3381-3385.
62. Kip1 in human lung cancers differential changes in small cell and non-small cell carcinomas Cancer Research. 58:1998;1042-1047.
63. Kip1 in non-small cell lung cancer a prognostic factor independent of Ras Cancer Research. 59:1999;684-688.
64. Ishihara S., Minato K., Hoshino H., Saito R., Hara F., Nakajima T., Mori M. The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer. its immunohistochemical evaluation using biopsy specimens Lung Cancer. 26:1999;187-194.
65. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
66. Ljungman M. Dial 9-1-1 for p53. mechanisms of p53 activation by cellular stress Neoplasia. 2:2000;208-225.
67. Chiarugi V., Magnelli L., Cinelli M., Ruggiero M. Oncogenes, p53, and tumor angiogenesis. Journal of Clinical Research and Clinical Oncology. 124:1998;523-552.
68. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene. clues to cancer etiology and molecular pathogenesis Cancer Research. 54:1994;4855-4878.
69. Kirsch D.G., Kastan M.B. Tumor-suppressor p53. implications for tumor development and prognosis Journal of Clinical Oncology. 16:1998;3158-3168.
70. Mitsudomi T., Hamajima N., Ogawa M., Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer. a meta-analysis Clinical Cancer Research. 6:2000;4055-4063.
71. Tammemagi M.C., McLaughlin J.R., Bull S.B. Meta-analysis of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemic Biomarkers Prevention. 8:1999;625-634.
72. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., Doshi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Research. 52:1992;4828-4831.
73. Harpole D.H. Jr., Herndon J.E., Wolfe W.G., Iglehart J.D., Marks J.R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Research. 55:1995;51-56.
74. Dalquen P., Sauter G., Torhorst J., Schultheiss E., Jordan P., Lehmann S., Soler M., Stulz P., Mihatsch M.J., Gudat F. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. Journal of Pathology. 178:1996;53-58.
75. Fukuyama Y., Mitsudomi T., Sugio K., Ishida T., Akazawa K., Sugimachi K. K-ras and p53 mutations are an independent unfavorable prognostic indicator in patients with non-small cell lung cancer. British Journal of Cancer. 75:1997;1125-1130.
76. Konishi T., Lin Z., Fujino S., Kato H., Mori A. Association of p53 protein expression in stage I lung adenocarcinoma with reference to cytological subtypes. Human Pathology. 28:1997;544-548.
77. Kwiatkowski D.J., Harpole D.H., Godleski J., Herndon II J.E., Shieh D.-.B., Richards W., Blanco R., Xu H.-.J., Strauss G.M., Sugarbaker D.J. Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients. clinical implications Journal of Clinical Oncology. 16:1998;2468-2477.
78. Hussain S.P., Harris C.C. Molecular epidemiology of human cancer. contribution of mutation spectra studies of tumor suppressor genes Cancer Research. 58:1998;4023-4037.
79. Tomizawa Y., Kohno T., Fujita T., Kiyama M., Saito R., Noguchi M., Matsuno Y., Hirohashi S., Yamaguchi N., Nakajima T., Yokota J. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung cancer. Oncogene. 18:1999;1007-1014.
80. Adams J.M., Cory S. The Bcl-2 protein family. arbiters of cell survival Science. 281:1998;1322-1326.
81. Pezzella F., Turley H., Kuzu I., Tungekar M.F., Dunnill M.S., Pierce C.B., Harris A., Gatter K.C., Mason D.Y. bcl-2 protein in non-small cell lung carcinoma. New England Journal of Medicine. 329:1993;690-694.
82. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C.A., Basolo F., Bevilacqua G. Bcl-2 protein. a prognostic factor inversely correlated to p53 in non-small cell lung cancer British Journal of Cancer. 71:1995;1003-1007.
83. Ritter J.H., Dresler C.M., Wick M.R. Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma. Human Pathology. 26:1995;1227-1232.
84. Anton R.C., Brown R.W., Younes M., Gondo M.M., Stephenson M.A., Cagle P.T. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer. analysis of 427 cases Human Pathology. 28:1997;1079-1082.
85. Apolinario R.M., van der Valk P., de Jong J.S., Deville W., van Ark-Otte J., Dingemans A.-.M.C., van Mourik J.C., Postmus P.E., Pinedo H.M., Giaccone G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer. Journal of Clinical Oncology. 15:1997;2456-2466.
86. Fleming M.V., Guinee D.G., Chu W.S., Freedman A.N., Caporaso N.E., Bennett W.P., Colby T.V., Tazelaar H., Abbondanzo S.L., Jett J., Pairolero P., Trastek V., Liotta L.A., Harris C.C., Travis W.D. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Human Pathology. 29:1998;60-64.
87. Burke L, Khan MA, Freedman AN, Gemma A, Ruswin M, Guinee DG, Bennett WP, Caporaso NE, Fleming MV, Travis WD, Colby TV, Trastek V, Pairolero PC, Tazelaar HD, Midthun DE, Liotta LA, Curtis CC. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Research 1998;2533-6.
88. Fontanini G., Vignati S., Boldrini L., Chine S., Silvestri V., Lucchi M., Mussi A., Angeletti A.C., Bevilacqua G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clinical Cancer Research. 3:1997;861-865.
89. Shibusa T., Shijubo N., Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clinical Cancer Research. 4:1998;1483-1487.
90. Ruotsalainen S.P., Mattson K., Joensuu T.T. High pre-treatment level of serum vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. International Journal of Cancer. 79:1998;144-146.
91. Achiwa H., Yatabe Y., Hida T., Kuroishi T., Koxaki K., Nakamura S., Ogawa M., Sugiura T., Mitsudomi T., Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinoma. Clinical Cancer Research. 5:1999;1001-1005.
92. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., Feng L., Hong W.K., Xu X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clinical Cancer Research. 7:2001;861-867.
93. Brabender J., Park J., Metzger R., Schneider P.M., Lord R.V., Holscher A.H., Danenberg K.D., Danenberg P.V. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Annals of Surgery. 235(3):2002;440-443.
94. Fong K.M., Kida Y., Zimmerman P.V., Smith P.J. TIMP-1 and adverse prognosis in non-small cell lung cancer. Clinical Cancer Research. 2:1996;1369-1372.
95. Passlick B., Sienel W., Seen-Hibler R., Wockerl W., Thetter O., Mutschler W., Pantel K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clinical Cancer Research. 6:2000;3944-3948.
96. Ylisirnio S., Hoyhtya M., Turpeenniemi-Hujanen T. Serum matrix metalloproteinase -2, -9 and tissue inhibitors of metalloproteinases. -1, -2 in lung cancer TIMP-1 as a prognostic marker Anticancer Research. 20:2000;1311-1316.
97. D'Amico T.A., Massey M., Herndon J.E., Moore M.-.B., Harpole D.H. A biologic risk model for stage I lung cancer. immunohistochemical analysis of 408 patients with the use of 10 molecular markers Journal of Thoracic and Cardiovascular Surgery. 117:1999;736-743.
98. Koo H., Gray-Goodrich M., Kohlhagen G McWilliams M.J., Jeffers M., Vaigro-Wolff A., Alvord W.G., Monks A., Paull K.D., Pommier Y., Vande Woude G.F. The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. Journal of National Cancer Institute. 91:1999;236-241.
99. Schiller J., Adak S., Feins R., Keller S.M., Fry W.A., Livingston R.B., Hammond E.M., Wolf B., Sabatini L., Jett J., Kohman L., Johnson D.H. Lack of prognostic significance of p53 and K-RAS mutations in primary resected non-small cell lung cancer on E4592. a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy Journal of Clinical Oncology. 19:2001;448-457.
100. Teman S., Flahault A., Perie S., Monceaux G., Coulet F., Callard P., Bernaudin J.-.F., St Guily J.L., Fouret P. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. Journal of Clinical Oncology. 18:2000;385-394.
101. Cabelguenne A., Blons H., de Waziers I., Carnot F., Houllier A.-.M., Soussi T., Brasnu D., Beaune P., Laccourreye O., Laurent-Puig P. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma a prospective series Journal of Clinical Oncology. 18:2000;1465-1473.
102. Tanaka F., Otake Y., Yanagihara K., Yamada T., Miyahara R., Kawano Y., Li M., Inui K., Wada H. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. British Journal of Cancer. 84:2001;263-269.
103. Tsai C., Chang K., Perng R.-.P., Mitsudomi T., Chen M.-.H., Kadoyama C., Gazdar A.F. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. Journal of National Cancer Institute. 85:1993;897-901.
104. neu European Respiratory Journal. 13:1999;424-429.
105. Graziano S., Kern J., Herndon J., Tatum A., Brisson M.L., Memoli V., Sugarbaker D., Skarin A.T., Kreisman H., Green M.R. Analysis of neuroendocrine markers HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer. a Cancer and Acute Leukemia Group B study Lung Cancer. 21:1998;203-211.
106. Monzo M., Rosell R., Sanchez J.J., Lee J.S., O'Brate A., Gonzalez-Larriba J.L., Alberola V., Lorenzo J.C., Nunez L., Ro J.Y., Martin C. Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations. Journal of Clinical Oncology. 17:1999;1786-1793.
107. Kelley M.J., Li S., Harpole D.H. Genetic analysis of the b-tubulin gene, TUBB, in non-small cell lung cancer. Journal of National Cancer Institute. 93:2001;1886-1888.
108. Tsurutani J., Komiya T., Uejima H., Tada H., Syunichi N., Oka M., Kohno S., Fukuoka M., Nakagawa K. Mutational analysis of the. β -tubulin gene in lung cancer Lung Cancer. 35:2002;11-16.
109. Franklin W.A. Diagnosis of lung cancer. pathology of invasive and preinvasive neoplasia Chest. 117:2000;80S-89S.
110. Witsuba I.I., Berry J., Behrens C., Maitra A., Shivaurkar N., Milchgrub S., Mackay B., Minna J.D., Gazdar A.F. Molecular changes in bronchial epithelium of patients with small cell lung cancer. Clinical Cancer Research. 6:2000;2604-2610.
111. Mulshine J.L., Cuttitta F., Bibro M., Fedorko J., Fargion S., Little C., Carney D.N., Gazdar A.F., Minna J.D. Monoclonal antibodies that distinguish non-small cell from small cell lung cancer. Journal of Immunology. 131:1983;497-502.
112. Tockman M.S., Gupta P.K., Myers J.D., Frost J.K., Baylin S.B., Gold E.B., Chase A.M., Wilkinson P.H., Mulshine J.L. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells. a new approach to early lung cancer detection Journal of Clinical Oncology. 6:1988;1685-1693.
113. Fielding P., Turnbull L., Prime W., Walshaw M., Field J.K. Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens. a clinical marker of early lung cancer detection Clinical Cancer Research. 5:1999;4048-4052.
114. Tockman M.S., Mulshine J.L., Piantadosi S., Erozan Y.S., Gupta P.K., Ruckdeschel J.C., Taylor P.R., Zhukov T., Zhou W.H., Qiao Y.L., Yao S.X. Prospective detection of preclinical lung cancer. results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression Clinical Cancer Research. 3:1997;2237-2246.
115. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis Proceedings of the National Academy of Sciences USA. 95:1998;11891-11896.
116. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., Belinsky S.A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Research. 60:2000;5954-5958.
117. INK4a promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in asymptomatic chronic smokers Journal of Clinical Oncology. 18:2000;3221-3229.
118. Sozzi G., Musso K., Ratcliffe C., Goldstraw P., Pierotti M.A., Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients. prospect for early diagnosis Clinical Cancer Research. 5:1999;2689-2692.
119. Mao L., Hruban R., Boyle J., Tockman M., Sidransky D. Detection of oncogenes mutations in sputum precedes diagnosis of lung cancer. Cancer Research. 54:1994;1634-1637.
120. Lubin R., Schlichtholz B., Teillaud J.L., Garay E., Bussel A., Wild C.P. P53 antibodies in patients with various types of cancer. assay, identification, and characterization Clinical Cancer Research. 1:1995;1463-1469.
121. Guinee D.G. Jr., Travis W.D., Trivers G.E., De Benedetti V.M.G., Cawley H., Welsh Ja., Bennett W.P., Jett J., Colby T.V., Tazelaar H., Abbondanzo S.L., Pairolero P., Trastek V., Caporaso N.E., Liotta L.A., Harris C.C. Gender comparisons in human lung cancer. analysis of p53 mutations, anti-p53 serum antibodies and c-erbB2 expression Carcinogenesis. 16:1995;993-1002.
122. Lotan R. Retinoids and chemoprevention of aerodigestive tract cancer. Cancer Metastasis Review. 16:1997;1405-1410.
123. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB Journal. 10:1996;940-954.
124. Martinet N., Alla F., Farrē G., Labib T., Drouot H., Vidili R., Picard E., Gaube M.-.P., Le Faou D., Siat J., Borelly J., Vermylen P., Bazarbachi T., Vignaud J.-.M., Martinet Y. Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. Cancer Research. 60:2000;2869-2875.
125. Ayoub J., Jean-François R., Cormier Y., Meyer D., Ying Y., Major P., Desjardins C., Bradley W.E.C. Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk. implication for chemoprevention of lung cancer Journal of Clinical Oncology. 17:1999;3546-3552.
126. Buccheri G., Ferrigno D. Lung tumor markers of cytokeratin origin. an overview Lung Cancer. 34(Suppl. 2):2001;S65-S69.
127. Ylisirniö S., Höyhtyä M., Makitäro R., Pääkkö P., Risteli J., Kinnula V.L., Turpeenniemi-Hujanen T., Jukkola A. Elevated serum levels of type I collagen degradation marker ICPT and tissue inhibitor of metalloproteinases (TIMP) 1 are associated with poor prognosis in lung cancer. Clinical Cancer Research. 7:2001;1633-1637.
128. Petricoin III E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
129. Garber M.E., Troyanskaya O.G., Schluens K., Petersen S., Thaesler Z., Pacyna-Gengelbach M., van de Rijn M., Rosen G.D., Perou C.M., Whyte R.I., Altman R.B., Brown P.O., Botstein D., Petersen I. Diversity of gene expression in adenocarcinoma of the lung. Proceedings of the National Academy of Sciences USA. 98:2001;13784-13789.
130. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., Ladd C., Beheshti J., Bueno R., Gillette M., Loda M., Weber G., Mark E.J., Lander E.S., Wong W., Johnson B.E., Golub T.R., Sugarbaker D.J., Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences USA. 98:2001;13790-13795.
131. Wigle D.A., Jurisica I., Radulovich N., Pintilie M., Rossant J., Liu N., Lu C., Woodgett J., Seiden I., Johnston M., Keshavjee S., Darling G., Winton T., Breitkreutz B.J., Jorgenson P., Tyers M., Shepherd F.A., Tsao M.-.S. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Research. 62:2002;3005-3008.